Silicon Biosystems Menarini has entered a collaboration with South Korea-based Macrogen to develop new clinical assays and procedures for precision medicine in cancer.

As part of the deal, Silicon Biosystems’ DEPArray digital-sorting technology will be combined with Macrogen’s next-generation sequencing capabilities to develop tests certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 by the Centers for Medicare & Medicaid Services (CMS) of the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The combination of Macrogen’s whole-genome, whole-exome and targeted sequencing capabilities with the DEPArray’s technology is expected to help resolve cellular heterogeneity of formalin-fixed paraffin-embedded (FFPE) biopsies and fine-needle aspiration (FNA) samples.

"Through DEPArray sorting, we can help rescue samples with a very low number of tumour cells."

Silicon Biosystems president and CEO Giuseppe Giorgini said: "Pure cells provide exact answers about all kinds of genomic variation and instability from the level of targeted cancer panels up to the whole genome level, making DEPArray sorting and sequencing an unparalleled tool for precision patient stratification.

"Furthermore, through DEPArray sorting, we can help rescue samples with a very low number of tumour cells, like FNAs and low-cellularity FFPE.

"We believe that Macrogen, with its proven NGS expertise, is an ideal partner to make such benefits available to patients and pharmaceutical companies through combined services provided in a CLIA environment."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new assays and procedures are expected to help deliver pure cancer and tumour-negative control cells, as well as other key cellular elements such as tumour-infiltrating lymphocytes from FFPE tumour samples.

Macrogen chairman Dr Jeong-Sun Seo said: "This collaboration between Macrogen and Silicon Biosystems Menarini for the development of tumour-cell specific cancer somatic variants analysis will bring the critical benefit of precision medicine to cancer patients in urgent need sooner than we expected."

Macrogen is focused on providing DNA sequencing, next-generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services in around 120 countries.